India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly

NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip